Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-03

Clinical Trial Update: Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating roflumilast in combination with antipsychotics in schizophrenia; results from the proof-of-mechanism trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Roflumilast (roflumilast)

Snippet

Sponsor: Takeda | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2016-10-03